The company said the therapy is the first allogenic therapy developed with its Tmod technology to be tested in humans.

The agency is considering further regulatory action after a second Duchenne patient died from acute liver failure less than two months after receiving the gene therapy.

The firm is evaluating two dose levels of its nectin-4-targeted ADC plus Merck's Keytruda in a range of solid tumors.

The firm will evaluate VS-7375 as both monotherapy and in combination with Eli Lilly's EGFR inhibitor Erbitux in the study.

The firm hopes to overcome common dose-limiting toxicities with its PSMA-targeted radiotherapy while boosting potency versus competitors.

UCLA-led investigators say additional research is needed into why guideline-recommended genetic testing remains low among ...

In a Phase I study, previously treated pediatric SMA patients exhibited reductions in a marker of neurodegeneration after salanersen treatment.

NEW YORK – Nuvalent is preparing to submit a rolling new drug application to the US Food and Drug Administration, seeking approval for its ROS1 inhibitor zidesamtinib as a treatment for patients with ...

NEW YORK – Revolution Medicines on Tuesday announced a partnership with Royalty Pharma that provides $2 billion in flexible funding to support the development of Revolution's pipeline of RAS-targeted ...